ONATASERTIB
Neuroendocrine Tumors of Non-Pancreatic Origin
CelgeneSmall moleculePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 30/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Neuroendocrine Tumors of Non-Pancreatic Origin cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Paltusotine Crinetics Pharmaceuticals Inc. | Phase 3 | BB |
Oxodotreotide RayzeBio, Inc. | Phase 3 | BB |
Everolimus RayzeBio, Inc. | Phase 3 | B |
Lanreotide RayzeBio, Inc. | Phase 3 | B |
Octreotide Pamoate RayzeBio, Inc. | Phase 3 | B |
View all 30 →
Same molecule, other indications
ONATASERTIB is also rated in:
1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical CancerDormant
CC
Indicative ·
45 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →